References
- Steven H, Swerdlow EC, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer: Lyon: 2008.
- Reilly JT. Chronic neutrophilic leukaemia: a distinct clinical entity? Br J Haematol 2002; 116: 10–18.
- Stevenson JP, Schwarting R, Schuster SJ. Analysis of clonality using X-linked polymorphisms in a patient with multiple myeloma and myelofibrosis. Am J Hematol 1998; 59: 79–82.
- Kusaba N, Yoshida H, Ohkubo F, et al. [Granulocyte-colony stimulating factor-producing myeloma with clinical manifestations mimicking chronic neutrophilic leukemia]. [Rinsho ketsueki] Japanese J Clin Hematol 2004; 45: 228–232.
- Ito T, Kojima H, Otani K, et al. Chronic neutrophilic leukemia associated with monoclonal gammopathy of undetermined significance. Acta Haematologica 1996; 95: 140–143.
- Kohmura K, Miyakawa Y, Kameyama K, et al. Granulocyte colony stimulating factor-producing multiple myeloma associated with neutrophilia. Leuk Lymphoma 2004; 45: 1475–1479.
- Nagai M, Oda S, Iwamoto M, et al. Granulocyte-colony stimulating factor concentrations in a patient with plasma cell dyscrasia and clinical features of chronic neutrophilic leukaemia. J Clin Pathol 1996; 49: 858–860.
- Usuda H, Naito M, Ohyach K, et al. A case of multiple myeloma producing granulocyte colony-stimulating factor. Pathol Int 1997; 47: 866–869.
- Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol 2010; 3: 323–337.
- Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368: 1781–1790.
- Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27: 1870–1873.
- Blombery P, Kothari J, Yong K, et al. Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. Leuk Lymphoma 2014; 55: 1661–1662.
- Nedeljkovic M, He S, Szer J, et al. Chronic neutrophilia associated with myeloma: is it clonal? Leuk Lymphoma 2014; 55: 439–440.
- Erber WN, Reilly JT. Chronic neutrophilic leukaemia with plasma cell dyscrasia: friends or relatives? Leuk Lymphoma 2014; 55: 240–242.
- Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genet 2013; 45: 18–24.
- Damm F, Itzykson R, Kosmider O, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013; 27: 1401–1403.
- Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 2013; 27: 1852–1860.
- Tyner JW, Yang WF, Bankhead A III, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res 2013; 73: 285–296.
- Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nature Genet 2013; 45: 942–946.
- Schinzel A, Giedion A. A syndrome of severe midface retraction, multiple skull anomalies, clubfeet, and cardiac and renal malformations in sibs. Am J Med Genet 1978; 1: 361–375.
- Cristobal I, Garcia-Orti L, Cirauqui C, et al. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011; 25: 606–614.
- Hou HA, Kuo YY, Tang JL, et al. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Am J Hematol 2014; 89: 181–186.
- Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108: 1724–1732.
- Nam S, Williams A, Vultur A, et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 2007; 6: 1400–1405.
- Wildes TM, Procknow E, Gao F, et al. Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk Lymphoma 2009; 50: 137–140.
- Haubeiss S, Schmid JO, Murdter TE, et al. Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer 2010; 9: 168. doi: 10.1186/1476-4598-9-168.